Tenax Therapeutics, Inc. (TENX)
$1.60-12.57%Close
BUYCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $28M
- Beta
- 0.92
- P/E (TTM)
- -1.07
- Short % float
- 43.45%
- Days to cover
- 2.4
- SI change
- +30.5%
- 1W
- -17.10%
- 1M
- -13.98%
- vs SPY 1W
- -16.96%
- vs SPY 1M
- -16.48%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 14
- VALUE
- 29
- GROWTH
- 39
- GARP
- 0
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-36.9%
REV YoY-
ROE-61.5%
EPS YoY-
ROA-53.3%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.07
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.72
P/FCF-
EV/EBITDA1.15
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO15.07
ND/EBITDA-
BETA0.92
Company news
FAQ
- What is LOPJLB’s current signal on TENX?
- LOPJLB’s latest quantitative signal on Tenax Therapeutics, Inc. (TENX) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is TENX in?
- Tenax Therapeutics, Inc. (TENX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Tenax Therapeutics, Inc. (TENX) do?
- Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to m…